Castle Biosciences Stock News

Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Castle Biosciences (NASDAQ:CSTL) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.48 (-108.7% Y/Y) and…

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PALM BEACH, FL , Feb. 18, 2022 /PRNewswire/ -- PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread of the disease by implementing necessary measures and increasing sample testing. The growing demand for COVID-19 diagnostic procedures and products alone has created immense opportunities in the healthcare industry, thus augmenting the market value. According to Fortune Business Insights: "The PCR technique segment dominated the market in 2020. The dominance is attributable to the increased quantification of patent samples by the use of PCR. PCR adoption has also contributed to the considerable growth of the segment. Moreover, the launch of new PCR-based detection techniques is like to surge the demand of for PCR instruments in the upcoming years." For example, the emergence of the COVID-19 pandemic has led to an explosion of research on various combinations of compounds in laboratories to develop COVID-19 diagnostics and therapies.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.

Related Stocks: PING , RLJ , DEA , CSGS , ABBV , HRTX , AVGOP.PFD , WFCPL.PFD , CSTL , DHRPA.PFD , BACPL.PFD , VERX , COR , VNT , LRCX , APLS , SEDG , Z ,

Castle Biosciences (CSTL) said a study showed DecisionDx-SCC provides significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous

Castle Biosciences (CSTL) said a study showed that the combined application of DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq allows for highly accurate analysis of RNA and DNA

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at the 24th Annual Needham Growth Conference, Jan. 10, 2022, at 12:30 p.m. Eastern ti

EMC Capital Management grew its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 9.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,847 shares of the company’s stock after purchasing an additional 2,154 shares during the period. Castle Biosciences makes up approximately 0.9% […]

Wall Street brokerages expect that Castle Biosciences, Inc. (NASDAQ:CSTL) will announce $23.43 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Castle Biosciences earnings, with the highest sales estimate coming in at $23.45 million and the lowest estimate coming in at $23.40 million. Castle Biosciences posted sales of [] The post Zacks: Brokerages Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Announce Quarterly Sales of $23.43 Million appeared first on ETF Daily News .

Castle Biosciences, Inc. (NASDAQ:CSTL) dropped 6.2% during mid-day trading on Thursday . The company traded as low as $42.94 and last traded at $42.94. Approximately 5,706 shares changed hands during trading, a decline of 98% from the average daily volume of 243,368 shares. The stock had previously closed at $45.76. CSTL has been the topic []